What does China's pharmaceutical enterprises rely on to win market voice?

Pharmaceutical Network Market Analysis in recent years, the pharmaceutical industry has been rapid development, the industry said that the overall development trend of the pharmaceutical industry in the future is very clear, the state to promote the implementation of a healthy China strategy, the enhancement of national health awareness also promote the continuous growth of pharmaceutical market demand, the pharmaceutical industry will usher in a period of great changeand and opportunityFor the field of medicine, which has very high barriers to science and technology, it is necessary for pharmaceutical enterprises to win the market voice by adhering to innovation and leading the development
In the future, pharmaceutical companies want to develop at a high speed, need to pay attention to research and development, to be able to have enough new products to continue to come out, in order to become a large market capitalization companiesIn the wave of pharmaceutical industry development, policy, technology, product changes, innovation and high-quality development should be the core driving force of enterprises and adhere to, only through continuous innovation, to provide patients with accurate efficacy, reliable quality products, enterprises can tomorrow
It is understood that since 2017, China's innovative pharmaceutical industry policy support increased, has issued a number of policies, the development of the innovative pharmaceutical industry policy environment has improved significantlyThe encouragement of drug innovation, the acceleration of review and approval, the implementation of the system of listing licensees, the verification of clinical experimental data, the structural control of medical insurance, etc., have all played a strong shot in the research and development and production of innovative drugs in China, and the research and development of innovative drugs with the core goal of tackling tumors has thus entered a growth outbreak period, and it is expected that the next few years will be the golden period of intensive approval of innovative drugs for each pharmaceutical enterprise
As the core asset of the sustainable development of major pharmaceutical companies, innovative medicine will become a new driving force to accelerate innovation in the pharmaceutical industryIn recent years, the number of new drug declarations in China has shown an accelerated growth trendIn 2017, there were 175 new drug declarations, up 47% from the previous year, and a CAGR of 32% in 2011-2017, and China is ushering in a spring of innovative drugs
In China, the development of innovative pharmaceutical industry has become a hot topic in the field of medical and health care, with the continuous improvement of the domestic innovation pharmaceutical industry environment, in the future, through resources, policies, demand, supply of multiple dimensions of power, China is expected to become the global center of drug innovation
However, from the perspective of research and development, to judge a company's research and development capabilities, on the one hand, the educational background of research and development personnel, on the other hand, the absolute amount of research and development expenditure and the proportion of sales revenue, which will become a measure of a company's future development of the core
For the development of innovative drugs, an enterprise said that 2020 is the year of reform, it will vigorously promote institutional reform, actively explore the development of professional managers, mixed reform, spin-off and listing and a series of work, to promote scientific and technological innovation, talent breeding, capital structure optimization, and so on, to achieve high-quality development"In 2020, we will strive to promote high-quality development, promote the innovation and reform of the institutional system, from traditional state-owned enterprises to modern state-owned enterprises, and accelerate the pace of transformation and upgrading of the four major sectors." The person involved said
If China is to become a big pharmaceutical country and a powerful pharmaceutical country, it must take the path of vigorously developing innovative medicines, and pharmaceutical enterprises will also increase their investment in research and development, and pharmaceutical enterprises that really have the strength of original research and innovation research and development will become bigger and biggerNow with the development of high-tech, drug innovation has caught the rapid progress of science and technology, the industry said, AI, cloud computing, big data, blockchain as the representative of the emerging technology and drug innovation in the field of combined applications are booming, the future is in the future
Emerging technologies and new service models are rapidly penetrating into all aspects of medical care, allowing pharmaceutical companies, consumers and pharmaceutical investors to obtain a more diversified approach to research and development production, drug purchase, investment, but also for The entire medical and health sector in China has brought new development opportunities